SETD2 and nonpapillary renal cell carcinoma: A study of over 1000 ccRCC patients reached similar conclusions by Manley BJ et al., who found that ccRCC patients with mutations in BAP1 and SETD2 were associated with short CSS and recurrence-free survival, respectively [42].